Stents, scaffolds and DCB

Giuseppe Di Gioia and Jens Flensted Lassen explore the essentials of the provisional stenting strategy for non-left main true bifurcation lesions. This stepwise approach offers simplicity while preserving flexibility: start with one stent in the main vessel, and keep the option open for a second if...

Robert Byrne and Bruno Scheller explore the current role of drug-coated balloon (DCB) angioplasty nearly two decades after its initial clinical use. This discussion covers when and how to apply DCB angioplasty effectively in everyday practice, focusing on lesion preparation for de novo coronary disease and...

The newly-updated PCR Textbook chapter on DCB: concept, uses, clinical data and advantages.

Which ballooning technique is best after main vessel stenting in bifurcation PCI? This two-part study compares two key approaches: PKP (POT, kissing balloon inflation, final POT) and PSP (POT, isolated side branch dilation, final POT) to determine the optimal strategy.

At two-year follow-up, the use of sirolimus-eluting cobalt-chromium DynamX Drug Eluting Coronary Bioadaptor System (Elixir Medical Corporation) resulted in fewer target lesion failure (TLF) compared with the Resolute Onyx contemporary drug-eluting stent.

Due to a lack of randomised evidence, this randomised controlled trial (RCT) aimed to compare the safety and efficacy of IVL and ELCA with RA in treating heavily calcified coronary lesions before drug-eluting stent implantation.

Watch the replay webinar with F. Ribichini, F. Jafary, Y. Onuma and B. Scheller to learn how to “control” dissections during lesion preparation, and much more!

Dive into six decades of innovation in transluminal angioplasty! Hosted by Jean Marco and Chiara De Biase, each episode features in-depth conversations with these visionary figures, offering historical perspectives and inspiring messages to shape the future of clinical practice. ...

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.